Patent Number: 6,169,068

Title: Pulmonary administration of soluble complement receptor-1 (sCR1) and its derivatives

Abstract: A method is disclosed for treating diseases or disorders involving complement by pulmonary administration of complement inhibitory proteins such as soluble complement receptor type 1 (sCR1). The present invention relates to the direct treatment of certain complement related disorders by administering complement inhibitory proteins via the pulmonary route, in particular, by direct delivery to the lungs by aerosolization of a complement inhibitory protein and subsequent inhalation.

Inventors: Levin; James L. (Wellesley, MA), Regal; Jean F. (Duluth, MN), Toth; Carol A. (Sharon, MA)

Assignee: Avant Immunotherpeutics, Inc.

International Classification: A61K 38/17 (20060101); C07K 14/435 (20060101); C07K 14/705 (20060101); A61K 038/17 (); A61K 009/12 (); A61K 009/14 ()

Expiration Date: 01/02/2018